Introduction
============

According to worldwide cancer statistics (Globocan 2012), lung cancer is the most commonly diagnosed cancer among men, and in women it is the third most commonly diagnosed ([@b1-ol-0-0-6274]). Approximately 2 million new cases of lung cancer and 1.5 million lung cancer related deaths are recorded each year ([@b2-ol-0-0-6274]). Mortality due to lung cancer is estimated to increase up to 10 million per year in another 15 years ([@b3-ol-0-0-6274]). There are two major types of lung cancer, *viz*., small cell lung cancer (SCLC), which is less common accounting for \~20% of the cancer cases, and non-small cell lung cancer (NSCLC), which is the most common, accounting for almost 85% of lung cancer cases ([@b4-ol-0-0-6274]). Despite the high incidence and associated mortality, the available treatment options and prognosis for NSCLC are not satisfactory. In a recent meta-analysis, we showed that exercise at medium to high level intensity is associated with lower risk of lung cancer, both in men and women, indicating the lifestyle-based benefits for reducing lung cancer risk ([@b5-ol-0-0-6274]). Platinum-doublet chemotherapy, which is the standard first-line therapy, has been shown to yield objective responses with a median overall survival (OS) of 8--10 months in approximately 30--40% of patients with NSCLC and there are significant safety issues ([@b6-ol-0-0-6274]). Considering that the efficacy of platinum-based therapies is dependent on the mutational/single nucleotide polymorphisms (SNP) status of the components of DNA-damage repair systems available in the target cancer cells, there can be significant individual differences in treatment responses. Thus, we showed earlier that the SNPs XRCC1Arg399Gln and XPG His46His are associated with significantly better treatment response in NSCLC patients to platinum-based chemotherapy ([@b7-ol-0-0-6274]). On the other hand, tyrosine kinase inhibitors (e.g., gefitinib, erlotinib, and afatinib) are found to be more effective with nearly 65% response rate and a median OS of 24--36 months in NCLSC patients with EGFR mutations ([@b8-ol-0-0-6274]). In addition to chemotherapy and chemoradiotherapy, immunological approaches have been shown to be effective in treating various cancers, including NSCLC. Significant advances have been made in the last 3 years in the development of immunotherapies for NSCLC. Immunotherapies include tumor antigen vaccination, monoclonal antibodies targeting checkpoint pathways and also activated immune cells ([@b8-ol-0-0-6274]--[@b10-ol-0-0-6274]). Several recent studies have shown the efficacy of immunotherapies against advanced stage NSCLC patients ([@b10-ol-0-0-6274]--[@b12-ol-0-0-6274]). Despite the promise of several immunotherapies, their efficacy has not been consistent as noted in the phase III FORTIS trial ([@b13-ol-0-0-6274]). Response to immunotherapies can also be dependent on many other factors, such as chemokines that influence immune cell function. Thus, we reported earlier that polymorphism (−2518A/G) in the gene coding for monocyte chemoattractant protein-1 (MCP-1) is associated with elevated risk for NSCLC. MCP-1 is known to be a tumor suppressor via pathways involving T-lymphocytes or independent of lymphocytes ([@b14-ol-0-0-6274]). Similarly, we also noted that the frequencies of polymorphisms in the human leukocyte antigen (HLA) system, which is involved in the regulation of immune response, HLA-A\*0201, A\*2601, B\*1518, B\*3802, DRB1\*0401, DRB1\*0402, and DRB1\*1201 are higher in the lung cancer patients than healthy controls ([@b15-ol-0-0-6274]), and affect the tumor immunity.

An earlier meta-analysis of 12 randomized controlled trials of immunotherapies indicated a beneficial effect on OS with few adverse effects ([@b6-ol-0-0-6274]). However, in this analysis, 3 monoclonal antibody (Mab)-based trials with cetuximab (targets EGFR) and one trial with trastuzumab (targets HER2) as NSCLC Mab therapy subgroup, whereas these actually are related to the growth factors and not immune system. A recent meta-analysis of several clinical trials of immunotherapies, including therapeutic vaccines and immune checkpoint inhibitors showed that immunotherapies are well tolerated in advanced NSLSC patients and improve OS and that specific antitumor immune response simulating agents are more efficacious than immunomodulatory type agents ([@b16-ol-0-0-6274]). A comparison of tumor vaccine-based therapies with cellular immunotherapies, in a meta-analysis revealed that cellular immunotherapies are more effective in improving OS and progression-free survival (PFS) in NSCLC patients ([@b12-ol-0-0-6274]). However, in many of these meta-analyses, the number of included studies and the total number of patients was lower and also, as mentioned above, inclusion of unrelated therapies could have complicated the outcomes and conclusions. Also, discordant results were seen in certain clinical trials using immunotherapies against NSCLC as the promising phase II study results were not observed in phase III study, leading to premature termination of the clinical trials, questioning the efficacy of immunotherapy ([@b17-ol-0-0-6274]). We have now conducted a meta-analysis of 13 clinical trials assessing the efficacy and safety of Mab therapies directed against tumor antigens and tumor antigen-based vaccination therapies, as compared to chemotherapy/chemoradiotherapy in NSCLC patients.

In the present meta-analysis, we analyzed results from clinical trial studies that simultaneously compared immunotherapies with placebo or chemotherapy/radiotherapy to assess the beneficial effects of immunotherapies collectively or separately in improving OS and PFS of NSCLC patients. Besides efficacy, we also examined if immunotherapies are better in terms of safety, by looking at the treatment-related adverse effects.

Materials and methods
=====================

### Criteria for considering studies for this review

Randomized controlled phase II and III clinical trials on patients with NSCLC at stage III and IV, with histological confirmation are included in this analysis. In these studies, immunotherapies were administered to patients along with chemotherapy or as monotherapy and the treatment effects were compared to a control group of patients, who received either chemotherapy alone or placebo. For the present meta-analysis, we have included only vaccine-based and Mab-based immunotherapy studies and not the immune cell-based adoptive immunotherapy clinical trials. Studies that did not include proper controls were excluded from this meta-analysis. Most of the patients in the included studies had Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2 ([@b18-ol-0-0-6274]). Patients were excluded if they were on concurrent systemic steroids, with metastases in bone requiring immediate therapy, uncontrolled pleural effusions, serious non-malignant disease or previous malignancies or if they had myocardial infarction or other cardiovascular disease in the 6-month period prior to study. Approximately half of the included studies were open-label, whereas the remaining are double-blind studies.

### Search methods

Literature search was completed on 10 January 2017 and publications that included complete relevant information and data were collected. Following databases were searched: PubMed, Google Scholar, Scopus, Web of Science and Cochrane Central Register. Search MeSH terms included lung cancer, NSCLC, immunotherapy, vaccine therapy for NSCLC, vaccination for NSCLC, OS, clinical trials, PFS and Mab therapy. All the relevant publications only in English language were collected and were initially screened at the title and abstract level. Only clinical trials at phase II and III level were included in this analysis. Full reports and supplemental information files were retrieved as per the relevance of the selected study.

### Data collection and analysis and quality assessment

All the authors of this meta-analysis participated in the screening of collected publications and data extraction. Data including patient baseline characteristics such as age, sex, description and dosages of the administered treatment, tumor histology, and disease stage, and treatment primary endpoint measurements (PFS events, OS) and treatment related adverse effects were collected, by filling out a pre-defined data collection form, from each included study. OS, which was defined as the time from randomization to censor or death due to any cause, was mostly reported as median months and for the purposes of meta-analysis, these values were converted to mean ± SD. The period from randomization of patients to the progression of disease (or death if it occurred first), during the study duration, as ascertained and documented by the study investigators, was defined as PFS. Treatment related adverse effects were evaluated to assess the safety of immunotherapy procedure, and the adverse events (scoring grade ≥3) reported in more than two clinical trials, as the number of patients were collected. These include both hematological and non-hematological effects. Hematological events recorded were anemia, neutropenia, thrombocytopenia and the non-hematological events include fatigue, vomiting, abdominal pain, fever, nausea, and anorexia/loss of appetite.

### Statistical analysis

Statistical analyses were conducted using the methods described by the Cochrane Collaboration guidelines for meta-analysis, using Review Manager (RevMan) version 5.3 software (the Cochrane Collaboration). As mentioned above, OS was mostly reported as median months and lower and upper limits of the range and for the purposes of meta-analysis, these values were converted to mean ± SD. Number of PFS events, were not given directly, was deduced from the PFS plots in the individual trials. The effect of immunotherapy on PFS and each of the adverse events were analyzed by Mantel-Haenszel statistics, odds ratios (OR) in the random-effect model, at 95% confidence intervals (CI). The effect of immunotherapy on OS was assessed by mean difference analyses in inverse variance (IV) fixed mode at 95% confidence intervals. Sensitivity analysis was performed by excluding one study at a time and also by removing study with highest weightage, among the included data to examine influence of bias on the deduced statistical significance and interpretation. Risk ratios were calculated for adverse events and also for PFS at 95% confidence intervals.

Results
=======

Search from all the databases yielded 12,338 studies, which contained the search MeSH terms either in the title or in the abstract. Exclusion of studies was done through the participation of all authors, who read the abstracts and a collective decision was adopted. A total of 13 studies ([@b11-ol-0-0-6274],[@b19-ol-0-0-6274]--[@b29-ol-0-0-6274]) were identified on the basis of relevancy and inclusion/exclusion criteria and completeness of the data in the study ([Fig. 1](#f1-ol-0-0-6274){ref-type="fig"}). As immunotherapy of NSCLC is a recently developed treatment approach, all the studies identified are published after 2011. The total number of patients in all the included studies was 6,585 and the number of patients who received immunotherapy was 3,513, whereas the control group patients who received chemotherapy or placebo were 3,072 ([Fig. 1](#f1-ol-0-0-6274){ref-type="fig"}).

### Patient characteristics

The demographic and baseline characteristics of patients in the included studies are given in [Table I](#tI-ol-0-0-6274){ref-type="table"}. Average age of the patients in both immunotherapy and control groups was \~62 years. Nearly 64.3% of the patients who received immunotherapy were males while in control chemotherapy group 62.9% were males. Tumors were of adenocarcinoma type, by histological examination in nearly two-thirds of the patients in both immunotherapy group (n=2,155) and in control group (n=2,009) and next major histological type was squamous cell carcinoma ([Table I](#tI-ol-0-0-6274){ref-type="table"}). ECOG performance status, which is an indicator of the patient\'s daily living ability and the progress of disease, is predominantly 0 or 1 for most of the included patients, in both immunotherapy and chemotherapy/placebo groups ([@b18-ol-0-0-6274]). Majority of the patients are restricted for strenuous physical activity, even though they could carry out light and sedentary work.

In the present meta-analysis study, only antibody-based and vaccine-based immunotherapies are included. Cellular therapy studies were not included as many of these studies are at early phase I stage. Out of the 13 studies, nine were antibody-based immunotherapies, while the remaining four were vaccine-based. Antibody therapies included ipilimu-mab, an anti-cytotoxic T-cell lymphocyte-4 Mab ([@b20-ol-0-0-6274]); nivolumab, a human IgG4 PD-1 immune-checkpoint-inhibitor Mab ([@b11-ol-0-0-6274],[@b21-ol-0-0-6274]); atezolizumab, another anti-PD-L1 Mab ([@b22-ol-0-0-6274],[@b26-ol-0-0-6274]); pembrolizumab, also known as MK-3475, a human IgG4 PD-1 Mab ([@b23-ol-0-0-6274],[@b25-ol-0-0-6274]); and bevacizumab, a recombinant, anti-vascular endothelial growth factor Mab ([@b28-ol-0-0-6274]). Vaccine-based immunotherapies included TG4010 genetic vaccine, which is a suspension of a recombinant modified vaccinia virus strain Ankara (MVA), coding for the MUC1 tumor-associated antigen and interleukin-2 ([@b19-ol-0-0-6274],[@b24-ol-0-0-6274]); tecemotide (L-BLP25), a tumor associated MUC1 antigen-specific immunotherapy, that is capable of inducing a T-cell response to MUC1 ([@b27-ol-0-0-6274]) and belagenpumatucel-L, an allogeneic whole tumor cell vaccine consisting of four pCHEK/HBA2 (human transforming growth factor-β2-antisense vector)-transfected NSCLC cell lines ([@b29-ol-0-0-6274]). Immunotherapy dosages and chemotherapy dosages are shown in [Table I](#tI-ol-0-0-6274){ref-type="table"}. Dosage of antibodies varied depending on the study and antibody used. Thus, ipilimumab was given at 10 mg/kg as four doses plus paclitaxel and carboplatin followed by two doses of placebo plus paclitaxel and carboplatin, intravenously every 3 weeks for up to 18 weeks ([@b20-ol-0-0-6274]). Nivolumab was given at 3 mg/kg, every 2 weeks, for 11 to 13.2 months ([@b11-ol-0-0-6274],[@b21-ol-0-0-6274]). Atezolizumab was given at 1.2 g fixed dose, intravenously on day 1, every 3 weeks, for at least 9 months ([@b22-ol-0-0-6274],[@b26-ol-0-0-6274]). Pembrolizumab was given at 2 mg or 10 mg/kg, every 3 weeks for 24 months ([@b23-ol-0-0-6274]) or at 200 mg every 3 weeks in 35 cycles ([@b25-ol-0-0-6274]). Bevacizumab was given at 15 mg/kg, intravenously on day 1, every 3 weeks + erlotinib 150 mg/day ([@b28-ol-0-0-6274]). TG4010 genetic vaccine was administered at 10^8^ pfu along with cisplatin 75 mg/m^2^ on day 1; gemcitabine 1.25 g/m^2^ on day 1 and 8, every 3 weeks in 6 cycles ([@b19-ol-0-0-6274],[@b24-ol-0-0-6274]). Tecemotide was administered subcutaneously, as 806 µg lipopeptide with lipid-A and liposome forming lipids ([@b27-ol-0-0-6274]). Belagenpumatucel-L was given intradermally at a dose of 2.5×10^7^ total cells ([@b29-ol-0-0-6274]). Chemotherapy generally included carboplatin, paclitaxel, docetaxel, cisplatin and gemcitabine. In one study ([@b28-ol-0-0-6274]), EGFR inhibitor, erlotinib was used as chemotherapy agent in control group patients. Where chemotherapy was not the regimen for control group patients, vehicle (used for immunotherapy) placebo (intralipid or liposome forming lipids) was given.

### Effect of immunotherapy on PFS and OS

In pooled OR analysis (Mantel-Haenszel, random) of both types of immunotherapies, PFS was found to be significantly increased ([Fig. 2A](#f2-ol-0-0-6274){ref-type="fig"}) in a higher number of patients as compared to chemotherapy/placebo control group (OR 1.81, 95% CI 1.36, 2.42; P\<0.0001). Further separate analysis of antibody therapy also revealed a significant beneficial effect on PFS in antibody receiving patients ([Fig. 2B](#f2-ol-0-0-6274){ref-type="fig"}) as compared to control group (OR 2.05, 95% CI 1.42, 2.94; P\<0.0001). Even though the vaccine therapy-receiving patients also showed better PFS compared to control group ([Fig. 2C](#f2-ol-0-0-6274){ref-type="fig"}), the statistical significance (OR 1.31, 95% CI 1.05, 1.63; P\<0.01) was not as high as in the case of antibody therapy. These results are in accordance with earlier results of a pooled analysis of the beneficial effects of immunotherapies ([@b12-ol-0-0-6274]). Similar results were obtained by risk ratio (RR) analysis ([Table II](#tII-ol-0-0-6274){ref-type="table"}). Thus, RR for both types of immunotherapies was 1.297 (95% CI 1.211, 1.389; P=0) and for Mab therapy RR was 1.335 (95% CI 1.222, 1.458; P=0). But RR for vaccine therapy was 1.063 and was not significant (95% CI 0.96, 1.176; P=0.239).

OS was significantly enhanced by both the immunotherapies as compared to chemotherapy/placebo controls ([Fig. 3A](#f3-ol-0-0-6274){ref-type="fig"}), as revealed by mean difference analysis in IV fixed mode (P\<0.00001). Unlike in the case of PFS, OS was greatly improved by both antibody-based therapy ([Fig. 3B](#f3-ol-0-0-6274){ref-type="fig"}; P\<0.00001) and vaccine-based therapy ([Fig. 3C](#f3-ol-0-0-6274){ref-type="fig"}; P\<0.00001). These results are in agreement with earlier findings showing the beneficial effects of immunotherapies on OS ([@b12-ol-0-0-6274],[@b16-ol-0-0-6274]).

### Effect of immunotherapies on treatment related adverse effects

Earlier studies indicated that hematological adverse effects were relatively lower in patients treated with immune check point inhibitors whereas in vaccine treated patients these effects were observed often ([@b16-ol-0-0-6274]). In the present meta-analysis (OR, Mantel-Haenszel, random), we observed that among the hematological adverse effects ([Fig. 4](#f4-ol-0-0-6274){ref-type="fig"}), anemia ([Fig. 4A](#f4-ol-0-0-6274){ref-type="fig"}; OR 0.27, 95% CI 0.15, 0.49; P\<0.0001) and neutropenia ([Fig. 4B](#f4-ol-0-0-6274){ref-type="fig"}; OR 0.09, 95% CI 0.02, 0.35; P=0.0004) are significantly lower in the immunotherapy-receiving patients ([Table III](#tIII-ol-0-0-6274){ref-type="table"}). However, events of thrombocytopenia ([Fig. 4C](#f4-ol-0-0-6274){ref-type="fig"}; OR 0.68, 95% CI 0.31, 1.51; P=0.34) are not different compared to chemotherapy/placebo control group. Thrombocytopenia events were reported only in approximately half of the included studies, unlike anemia and neutropenia. It has been shown earlier that thrombocytopenia events are similar or even more common in patients treated with immunomodulatory therapy ([@b16-ol-0-0-6274]). Among the non-hematological adverse effects, neither abdominal pain nor loss of appetite/anorexia was found to be different in the immunotherapy group ([Fig. 5A and B](#f5-ol-0-0-6274){ref-type="fig"}). However, fatigue, which is a commonly seen adverse effect appeared to be much less common in the immunotherapy group, as compared to the control chemotherapy/placebo group ([Fig. 5C](#f5-ol-0-0-6274){ref-type="fig"}; OR 0.67, 95% CI 0.52, 0.86; P\<0.001). A closer look at the data indicated that the number of patients with fatigue are much less in the antibody treated group, compared to their controls, whereas the events seems to be higher in the vaccine treated group. Other adverse effects including nausea, fever and vomiting are not much different in the immunotherapy group ([Fig. 6](#f6-ol-0-0-6274){ref-type="fig"}).

### Sensitivity analysis

In order to assess the robustness and to eliminate bias in the results, we re-analyzed the PFS and OS data by excluding individual trials with highest or lowest weightage. Such analysis did not qualitatively alter the obtained results and conclusions (data not elaborated). The OS benefits were still noted by immunotherapy over the chemotherapy/placebo controls. These conclusions are in agreement with earlier study ([@b16-ol-0-0-6274]), indicating that the benefits of immunotherapy are real and reproducible.

Discussion
==========

Chemotherapy and chemoradiotherapy are the first-line therapy for several cancers including NSCLC. Even though objective responses have been noted with many of these therapies, the efficacy is not observed in all the patients. Tyrosine kinase receptor inhibitors showed better effects on OS and PFS but due to resistance, their efficacy is lost and disease progression takes place. A better understanding of immune mechanisms and host antitumor responses led to the identification of potential therapeutic opportunities employing the components of immune system. These include different types of immunotherapies based on the use of monoclonal antibodies against tumor specific antigens and immune checkpoint pathways, immunomodulators, vaccination against tumor antigens and activated immune cells that attack tumors ([@b8-ol-0-0-6274],[@b30-ol-0-0-6274]). In the present meta-analysis, we examined the effectiveness of immunotherapies in improving PFS and OS. A total of 13 multicenter international phase II and III clinical trials addressing the efficacy of antibody therapies and vaccine therapies for treating NSCLC patients are included in this analysis. Among these studies, 9 were Mab-based therapies targeting different antigens and 4 were vaccine-based, with different immunogens. The immune check point pathway targets of the employed Mabs were programmed death-1 (PD1), programmed death ligand-1 (PD-L1) and cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4). Vaccine therapies were targeting the MUC1 tumor-associated antigen and using NSCLC cells transfected with human transforming growth factor-β2-antisense vector.

In line with other studies, we observed that immunotherapies offer better efficacy in terms of improved PFS and OS. Surprisingly, we observed that Mab therapies are more effective in improving PFS than the vaccine-based therapies ([@b25-ol-0-0-6274],[@b26-ol-0-0-6274],[@b28-ol-0-0-6274]). This can be because of the less number of vaccine-based studies and less number of patients in this analysis. An earlier meta-analysis indicated that immunotherapies have relatively stronger effect in improving PFS in low-stage NSCLC than in high-stage NSCLC patients ([@b12-ol-0-0-6274]). It was also observed that tumor histology is not related to disease progression. Combination of chemotherapy with immunotherapy has been proposed to have synergistic effect in inducing tumor cell death and by disrupting the immune evasion pathways of the tumor cells ([@b31-ol-0-0-6274]). Blockade of PD-1/PD-L1 signaling with checkpoint inhibiting antibodies has been shown to promote antitumor T-cell functionality ([@b32-ol-0-0-6274]). Efficacy of immunotherapies is likely related to the expression of the corresponding targets in the selected patient population ([@b33-ol-0-0-6274],[@b34-ol-0-0-6274]), which should be considered as a patient selection criterion for such clinical trials in future. However, for PD-1/PD-L1 expression this dependence may not always be true ([@b8-ol-0-0-6274],[@b21-ol-0-0-6274]).

Incidence of moderate adverse effects such as anorexia, abdominal pain, nausea, vomiting and fever appeared to be similar in chemotherapy and immunotherapy groups. But incidence of fatigue in immunotherapy receiving patients is less, suggesting an important beneficial effect by this therapy in improving the quality of life of patients. Also, the number of patients with anemia and neutropenia are less in immunotherapy group indicating a less secondary aggravated effect on hematological parameters. It has been recognized that chemotherapy and chemoradiotherapy in the treatment of NSCLC have adverse effects on bone marrow, leading to anemia, neutropenia and also thrombocytopenia ([@b35-ol-0-0-6274]). It is possible that immunotherapy assisted antitumor effects are helpful in strengthening the normal cellular homeostatic mechanisms and in overcoming the toxic side effects of chemotherapy. Better hematological parameters are likely further improve the general health and the daily living ability of the patient. Immunotherapy was earlier shown to be safe for agents that trigger specific antitumor reaction ([@b36-ol-0-0-6274],[@b37-ol-0-0-6274]). Thus, overall immunotherapies are safe and well tolerated and when combined with chemotherapy, they are somewhat protective against the toxic effects of chemotherapeutics, particularly on blood parameters. In as much as exercise also has beneficial effects in reducing the risk of lung cancer ([@b5-ol-0-0-6274]), it is of interest to assess whether a combination of immunotherapy with medium level of supervised exercise has any added benefit to the lung cancer patients, who are at 0--1 score for ECOG performance.

A major limitation of the present meta-analysis is the smaller number of included studies in vaccine-based immunotherapy group. Even though we combined both Mab-based therapies and vaccine-based therapies for comparison against chemotherapy controls for getting a larger picture of the effectiveness of immunotherapy, ideal comparison would be separate comparisons for these two types of immunotherapies. This was done for analyzing the effects on PFS and OS, where we noticed specific effects on PFS. Another limitation is that we included one Mab-based therapy study that targeted VEGF ([@b28-ol-0-0-6274]), instead of a direct tumor specific antigen, we included this study, as VEGF is important for neovascularization of the tumors and for tumor growth and is secreted by tumor cells. Another important limitation is the different treatment durations of the included studies, as this could have influenced the observed PFS and OS. In as much as female patients with NSCLC are known to have better survival and as it has been seen in the present study that in all the included studies there is a higher preponderance of males, it is important to separate males from females when analyzing the beneficiary effects of immunotherapy. This could not be done due to unavailability of individual patient data for all the included studies. Future analyses should take this into consideration to assess if males or females show a different/better response to a given treatment.

In conclusion, immunotherapy of NSCLC is beneficial and shows better efficacy than chemotherapy/placebo in improving PFS and OS. Besides, immunotherapies, due to their less adverse effects, seem to have beneficial impact on the quality of life of patients and the daily living ability.
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![Effect of immunotherapies on progression-free survival in NSCLC patients, compared to chemotherapy or placebo. Comparison of chemotherapy/placebo with both the (A) immunotherapies, (B) antibody therapy and (C) vaccine-based therapy. Forest plots of Odds ratio, analyzed by Mantel-Haenszel statistics in the random-effect model. NSCLC, non-small cell lung cancer.](ol-14-02-1568-g01){#f2-ol-0-0-6274}

![Effect of immunotherapies on overall survival of NSCLC patients, compared to chemotherapy or placebo. Comparison of chemotherapy/placebo with both the (A) immunotherapies, (B) antibody therapy and (C) vaccine-based therapy. Forest plots of mean difference analyzed by IV analysis in fixed-effect model. NSCLC, non-small cell lung cancer; IV, inverse variance.](ol-14-02-1568-g02){#f3-ol-0-0-6274}

![Effect of immunotherapies on adverse hematological effects. Comparison of chemotherapy/placebo with both the immunotherapies on the events of (A) anemia, (B) neutropenia and (C) thrombocytopenia. Forest plots of Odds ratio, analyzed by Mantel-Haenszel statistics in the random-effect model.](ol-14-02-1568-g03){#f4-ol-0-0-6274}

![Effect of immunotherapies on adverse non-hematological effects. Comparison of chemotherapy/placebo with both the immunotherapies on the events of (A) abdominal pain, (B) anorexia/loss of appetite and (C) fatigue. Forest plots of Odds ratio, analyzed by Mantel-Haenszel statistics in the random-effect model.](ol-14-02-1568-g04){#f5-ol-0-0-6274}

![Effect of immunotherapies on nausea, fever and vomiting. Comparison of chemotherapy/placebo with both the immunotherapies on the events of (A) nausea, (B) fever and (C) vomiting. Forest plots of Odds ratio, analyzed by Mantel-Haenszel statistics in the random-effect model.](ol-14-02-1568-g05){#f6-ol-0-0-6274}

###### 

Baseline characteristics of patients included in the meta-analysis.

  A, Immunotherapy                                                                                                                                                                                                                                                                                                                                                                                                                                       
  ------------------------------------------------ -------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------- ----------------- ------------ ---------- --------------------------------------------------------------------------------------------------------- ------------------------------- -------------------- ---- ------ -----
  Quoix *et al* ([@b19-ol-0-0-6274]) 2011          Controlled multicenter phase 2B                                TG4010 genetic vaccine (targets tumor MUC1)                                                                       74                58.5         71.6       10^8^ pfu; cisp75 mg/m^2^ on day 1; gem 1.25 g/m^2^ on day 1, 8; every 3 weeks × 6 cycles                 20                              53                   1    47     19
  Lynch *et al* ([@b20-ol-0-0-6274]) 2012          Randomized, double-blind phase 2B                              Ipilimumab (anti-cytotoxic T-cell lymphocyte-4 Mab)                                                               70                59           76         10 mg/kg Ipilimumab; pacli 175 mg/m2; carbo AUC 6; i.v. dosing every 3 weeks × 6 cycles                   19                              51                        35     21
  Borghaei *et al* ([@b21-ol-0-0-6274]) 2015       Randomized, open-label phase 3                                 Nivolumab human IgG4 PD-1 immune checkpoint inhibitor Mab                                                         292               61           52         3 mg/kg, every 2 weeks; for 13.2 months minimum                                                           84                              208                       268    7
  Brahmer *et al* ([@b11-ol-0-0-6274]) 2015        Randomized, open-label, multicenter, phase 3                   Nivolumab (IgG4 PD.1 Mab)                                                                                         135               62           82         3 mg/kg, every 2 weeks                                                                                    27                              106                              
  Fehrenbacher *et al* ([@b22-ol-0-0-6274]) 2016   Multicenter, open-label, randomized phase 2                    Atezolizumab (anti-PD-L1 Mab)                                                                                     144               62           65         Atezolizumab 1.2 g fixed, i.v., on day 1, every 3 weeks                                                   46                              96                        95     49
  Herbst *et al* ([@b23-ol-0-0-6274]) 2016         Multicenter, randomized, open-label, phase 2/3                 Pembrolizumab (MK-3475; human IgG4 PD-1 Mab)                                                                      344               63           62         Pembrolizumab, 2 mg/kg, every 3 weeks                                                                     112                             229                  3    240    76
  Herbst *et al* ([@b23-ol-0-0-6274]) 2016         Multicenter, randomized, open-label, phase 2/3                 Pembrolizumab (MK-3475; human IgG4 PD-1 Mab)                                                                      346               63           62         Pembrolizumab, 10 mg/kg, every 3 weeks                                                                    120                             225                  1    244    80
  Quoix *et al* ([@b24-ol-0-0-6274]) 2016          Randomized, double-blind multicenter, controlled phase 2b/3    TG4010 genetic vaccine                                                                                            111               63           65         10^8^ pfu; every week for 6 weeks then every 3 weeks; cisp 75mg/m^2^ on day 1; gem 1.25g/m2 on day 1, 8   33                              77                        95     13
  Reck *et al* ([@b25-ol-0-0-6274]) 2016           Open-label, multicenter, phase 3                               Pembrolizumab (MK-3475; human IgG4 PD-1 Mab)                                                                      154               64.5         59.7       Pembrolizumab, 200 mg every 3 weeks, 35 cycles                                                            54                              99                        125    29
  Rittmeyer *et al* ([@b26-ol-0-0-6274]) 2017      Open-label, multicenter randomized controlled phase 3          Atezolizumab (Anti-PD-L1 Mab)                                                                                     425               63           61         atezolizumab 1.2 g fixed, i.v., on day 1, every 3 weeks                                                   155                             270                       313    112
  Butts *et al* ([@b27-ol-0-0-6274]) 2014          START randomized, double-blind, multicenter phase 3            Tecemotide vaccine (MUC1-antigen-specific immunotherapy)                                                          829               61           68         Subcutaneous tecemotide (806 µg lipopeptide) + lipid-A+ liposome forming lipids                           398                             427                       289    401
  Herbst *et al* ([@b28-ol-0-0-6274]) 2011         Double-blind, multicenter placebo-controlled phase 3           Bevacizumab (recombinant, anti-vascular endothelial growth factor Mab)                                            319               65           54         Bevacizumab at 15 mg/kg, i.v., on day 1, every 3 weeks + erlotinib 150 mg/day                             129                             166                  23   242    23
  Giaccone *et al* ([@b29-ol-0-0-6274]) 2015       Phase 3 study                                                  Belagenpumatucel-L (whole tumor cell vaccine, of NSCLC) cells, transfected with a human TGF-β2-antisense vector   270               61.5         58         2.5×10^7^ total cells were injected intradermally                                                         119                             139                  7    162    65
                                                                                                                                                                                                                                                                                                                                                                                                                                                         
  B, Chemotherapy/placebo                                                                                                                                                                                                                                                                                                                                                                                                                                
                                                                                                                                                                                                                                                                                                                                                                                                                                                         
                                                                                                                                                                                                                                                                                                                                                                                        ECOG status (no. of patients)   Histology type (n)               
                                                                                                                                                                                                                                                                                                                                                                                                                                                         
  Author (ref.) year                               Study type                                                     Type of chemotherapy                                                                                              No. of patients   Age, years   Males, %   Chemotherapy dosage                                                                                       0                               1                    2    Ad     Sq
                                                                                                                                                                                                                                                                                                                                                                                                                                                         
  Quoix *et al* ([@b19-ol-0-0-6274]) 2011          Controlled multicenter phase 2B                                Cisplatin + gemcitabine                                                                                           74                58.5         73         Cisp 75 mg/m^2^ on day 1; gem 1.25 g/m^2^ on day 1, 8; every 3 weeks × 6 cycles                           20                                54                 0    55     11
  Lynch *et al* ([@b20-ol-0-0-6274]) 2012          Randomized double-blind phase 2B                               Paclitaxel + carboplatin                                                                                          66                62           74         Pacli 175 mg/m^2^; carbo AUC 6; i.v. dosing every 3 weeks × 6 cycles                                      15                                51                      38     15
  Borghaei *et al* ([@b21-ol-0-0-6274]) 2015       Randomized open-label, phase 3                                 Docetaxel                                                                                                         290               64           58         Docetaxel 75 mg/m^2^ every 3 weeks; for 13.2 months minimum                                               95                              194                       273    7
  Brahmer *et al* ([@b11-ol-0-0-6274]) 2015        Randomized open-label, multicenter phase 3                     Docetaxel                                                                                                         137               64           71         Docetaxel 75 mg/m^2^ every 3 weeks                                                                        37                              100                              
  Fehrenbacher *et al* ([@b22-ol-0-0-6274]) 2016   Multicenter, open-label, randomized phase 2                    Docetaxel                                                                                                         143               62           53         Docetaxel 75 mg/m^2^ on day 1, every 3 weeks                                                              45                                97                      95     48
  Herbst *et al* ([@b23-ol-0-0-6274]) 2016         Multicenter, randomized, open-label, phase 2/3                 Docetaxel                                                                                                         343               62           61         Docetaxel 75 mg/m^2^ on day 1, every 3 weeks                                                              116                             224                  1    240    66
  Quoix *et al* ([@b24-ol-0-0-6274]) 2016          Randomized, double-blind multicenter, controlled phase 2b/3    Cisplatin + gemcitabine                                                                                           111               59           63         Cisp 75 mg/m^2^ on day 1; gem 1.25 g/m^2^ 1, every 3 weeks + on day 1, 8; every 3 weeks × 6 cycles          35                              76                        90   13
  Reck *et al* ([@b25-ol-0-0-6274]) 2016           Open-label, multicenter, phase 3                               Carboplatin/cisplatin/paclitaxel/gemcitabine                                                                      151               66           62.9       Varying dosages                                                                                             53                              98                      124    27
  Rittmeyer *et al* ([@b26-ol-0-0-6274]) 2017      Open-label, multicenter randomized controlled phase 3          Docetaxel                                                                                                         425               64           61         Docetaxel 75 mg/m^2^, on day 1, every 3 weeks                                                             160                             165                       315    110
  Butts *et al* ([@b27-ol-0-0-6274]) 2014          START randomized, double-blind multicenter, phase 3            Placebo                                                                                                           410               61.5         68         Liposome forming lipids                                                                                   167                             239                       163    171
  Herbst *et al* ([@b28-ol-0-0-6274]) 2011         Double-blind, multicenter, placebo-controlled, phase 3 trial   Erlotinib (EGFR inhibitor)                                                                                        317               64.8         54         Erlotinib 150 mg/day                                                                                      121                             176                  20     90   17
  Giaccone *et al* ([@b29-ol-0-0-6274]) 2015       Phase 3 study                                                  Placebo                                                                                                           262               60.5         58         0.15% intralipid                                                                                          130                             119                  6    141    81

ECOG status, Eastern Cooperative Oncology Group performance status; Ad, adenocarcinoma; Sq, squamous cell carcinoma; pfu, plaque forming units; cisp, cisplatin; gem, gemcitabine; carbo, carboplatin; pacli, paclitaxel; Mab, monoclonal antibody.

###### 

Risk ratio analysis of PFS in antibody-based and vaccine-based immunotherapy groups vs. corresponding chemotherapy/placebo groups.

                                     Immunotherapy   Chemotherapy/placebo           95% CI                                              
  ---------------------------------- --------------- ---------------------- ------- -------- ------- ------- -------- -------- -------- --------
  PFS (for all immunotherapy)        1,329           1,914                  3,243   888      1,922   2,810   1.2968   1.2112   1.3885   0
  PFS (for antibody-based therapy)   802             1,427                  2,229   597      1,618   2,215   1.3349   1.2223   1.4579   0
  PFS (for vaccine-based therapy)    527             487                    1,014   291      304     595     1.0627   0.9604   1.1759   0.2392

PFS, progression-free survival; CI, confidence interval.

###### 

Risk ratio analysis of adverse effects in immunotherapy vs. chemotherapy/placebo groups.

                     Immunotherapy   Chemotherapy/placebo           95% CI                                              
  ------------------ --------------- ---------------------- ------- -------- ------- ------- -------- -------- -------- --------
  Anemia             270             1,994                  2,264   533      1,600   2,133   0.4773   0.4174   0.5457   0
  Neutropenia        155             2,109                  2,264   472      1,661   2,133   0.3094   0.2606   0.3673   0
  Thrombocytopenia     99              992                  1,091   106        909   1,015   0.8689   0.6698   1.1272   0.2899
  Abdominal pain       51            1,288                  1,339     45     1,159   1,204   1.0191   0.6877   1.51     0.925
  Nausea             544             3,014                  3,558   598      2,274   2,872   0.7343   0.661    0.8158   0
  Fatigue            766             2,792                  3,558   841      2,031   2,872   0.7352   0.6755   0.8002   0
  Vomiting           206             2,058                  2,264   265      1,868   2,133   0.7324   0.6165   0.87     0.0004
  Anorexia           553             2,934                  3,487   486      2,321   2,807   0.916    0.8195   1.0238   0.1221
  Fever              230             2,123                  2,353   184      2,039   2,223   1.1809   0.9815   1.4209   0.0781

CI, confidence interval.
